Clinical trials: Von Willebrand Diseases
Von Willebrand Disease
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
The main aim of the study is to check effectiveness, side effects, and tolerability of vonicog alfa (recombinant von Willebrand factor [rVWF]), with or without ADVATE, in the treatment and control of nonsurgical bleeding events…
- Trial name
- NCT02932618
- Testing
- Vonicog alfa, Antihemophilic Factor (Recombinant)
- Where
- 46 sites in United States, Austria and 11 more
- Volunteers
- 47 people
- Sponsor
- Baxalta now part of Shire
Platelet Dysfunction, Von Willebrand Diseases
Clinical Performance Evaluation of T-TAS 01 PL Chip
This study will measure primary hemostatic ability using the T-TAS 01 System with PL chip, with a comparison to clinical truth.
- Conditions
- Platelet Dysfunction, Von Willebrand Diseases, Healthy, Congenital Platelets Abnormality
- Trial name
- NCT03621020
- Testing
- T-TAS 01 PL Chip, PFA-100 Col/Epi and Col/ADP
- Where
- 6 sites in United States, France
- Volunteers
- 307 people, healthy volunteers welcome
- Sponsor
- Hikari Dx, Inc.
Von Willebrand Disease
Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age
The WIL-33 study aimed to determine the efficacy, pharmacokinetics, immunogenicity and safety of wilate as routine prophylaxis in up to 12 paediatric patients (eight evaluable) with severe von Willebrand Disease VWD (defined as…
- Trial name
- NCT04953884
- Testing
- Wilate
- Where
- 9 sites in United States, Czechia and 5 more
- Volunteers
- 12 people
- Sponsor
- Octapharma
Von Willebrand Disease
A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced)
As part of CSL Behring Canada's continued commitment to ensuring the safety of the new low volume preparation of Humate-P®, CSL Behring Canada proposes to conduct a prospective, multi-center structured data collection of routine…
- Trial name
- NCT00701545
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- CSL Behring
Von Willebrand Disease
A Study With OPTIVATE® in People With Von Willebrand Disease
The main objective of the study is to assess the pharmacokinetics of OPTIVATE® after a single dose of 80 IU/kg VWF:RCo. The secondary objectives of the study are to assess efficacy and safety of OPTIVATE® in long-term use over at…
- Trial name
- NCT00387192
- Testing
- Optivate
- Where
- 4 sites in Israel, United Kingdom
- Volunteers
- 26 people
- Sponsor
- Bio Products Laboratory
Stable Angina
CYP2C19 Gene Alteration and Thienopyridine Resistance in Percutaneous Coronary Intervention Study
Dual antiplatelet therapy with aspirin and thienopyridines decreases the rate of stent thrombosis in patients undergoing percutaneous coronary intervention (PCI).
- Trial name
- CALDERA-PCI (NCT00876512)
- Where
- Japan
- Volunteers
- 104 people
- Sponsor
- Kumamoto University
Hemophilia A, Severe
A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa
FREEDOM is a multicentre, open-label, single-arm, phase 3b study in Europe that aims to enrol approximately 90 previously treated severe haemophilia A patients aged ≥12 years, currently on prophylaxis.
- Trial name
- FREEDOM (NCT05817812)
- Testing
- Efanesoctocog alfa
- Where
- 30 sites in Austria, Croatia and 12 more
- Volunteers
- 93 people
- Sponsor
- Swedish Orphan Biovitrum
Von Willebrand Disease (VWD), Type 2
Efficacy and Safety of BT200 (Rondaptivon Pegol) in Patients With Type 2B Von Willebrand Disease
This randomized clinical trial with a cross-over design is being conducted at the Department of Clinical Pharmacology at the Medical University of Vienna, and a total of 4-6 patients with type 2B von Willebrand disease (VWD) will…
- Trial name
- BT200-VWD2B (NCT07273721)
- Testing
- BT200
- Where
- Austria
- Volunteers
- 6 people
- Sponsor
- Medical University of Vienna
Hemophilia A, Von Willebrand Disease
Efficacy and Safety of IL-11 in DDAVP Unresponsive
The purpose of this study is to determine the biologic efficacy and safety of rhIL-11 when given subcutaneously in adults with moderate or mild hemophilia A or Von Willebrand disease unresponsive to DDAVP.
- Trial name
- IL-11DDAVP (NCT00994929)
- Testing
- Neumega (Oprelvekin, Interleukin 11, IL-11)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Pittsburgh
Hemophilia A, Hemophilia B
World Bleeding Disorders Registry
The WBDR is an international observational disease registry of patients with hemophilia. It will provide a platform for a network of hemophilia treatment centres (HTCs) around the world to collect uniform and standardized patient…
- Conditions
- Hemophilia A, Hemophilia B, Von Willebrand Diseases
- Trial name
- WBDR (NCT03327779)
- Where
- Canada
- Volunteers
- 20,000 people
- Sponsor
- World Federation of Hemophilia
Von Willebrand Disease (VWD)
A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)
The main aim of the study is to evaluate the effectiveness of prophylaxis with vonicog alfa (recombinant von Willebrand factor [rVWF]) in children.
- Trial name
- NCT05582993
- Testing
- Vonicog Alfa, ADVATE
- Where
- 23 sites in United States, France and 4 more
- Volunteers
- 24 people
- Sponsor
- Takeda
Blood Loss, Surgical
Haemate HS in Patients With Severe Bleeding Undergoing Valve Replacement Due to Aortic Stenosis
Evaluation of efficacy by determination of transfusion requirements and safety by determination of adverse events in administration of Von Willebrand factor concentrate F VIII (Haemate).
- Trial name
- HAVAS (NCT00618293)
- Testing
- Haemate HS, NaCl-solution
- Where
- Germany
- Sponsor
- Heinrich-Heine University, Duesseldorf
Von Willebrand Diseases
The Lived Experience of People With Von Willebrand Disease
von Willebrand disease (vWD) is reported to be the most common bleeding disorder, with prevalence estimated at 1% of the general population.
- Trial name
- VWD360 (NCT06064643)
- Testing
- Online Survey, Qualitative Interview, Bleed Diary
- Where
- United Kingdom
- Volunteers
- 611 people
- Sponsor
- Haemnet